ArticleThe Journal of experimental medicine2017
A nonimmune function of T cells in promoting lung tumor progression.
Article in The Journal of experimental medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 46 citations in OpenAlex.
- Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).Annals of oncology : official journal of the European Society for Medical Oncology · 2018Trial
- CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses.Molecular cancer therapeutics · 2026Article
- Article
- Allospecific splenic Tr1 cells drive effector T cell exhaustion through up-regulated Areg-EGFR signaling to promote transplant tolerance.Science advances · 2026Article
- Foxp3Research square · 2025Article
- Heparan sulfate regulates amphiregulin programming of tissue reparative lung mesenchymal cells during influenza A virus infection in mice.Nature communications · 2025Article
- Terminal differentiation and persistence of effector regulatory T cells essential for preventing intestinal inflammation.Nature immunology · 2025Article
- Evaluation of pathological response to neoadjuvant chemotherapy in locally advanced cervical cancer.Journal of translational medicine · 2024Article
- Treg-tissue cell interactions in repair and regeneration.The Journal of experimental medicine · 2024Review
- Tissue adaptation of CD4 T lymphocytes in homeostasis and cancer.Frontiers in immunology · 2024Article
- Enhanced amphiregulin exposure promotes modulation of the high grade serous ovarian cancer tumor immune microenvironment.Frontiers in pharmacology · 2024Article
- Amphiregulin couples IL1RL1Science advances · 2023Article
- Regulation of the alveolar regenerative niche by amphiregulin-producing regulatory T cells.The Journal of experimental medicine · 2023Article
- Antitumour immunity regulated by aberrant ERBB family signalling.Nature reviews. Cancer · 2021Review
- Common clonal origin of conventional T cells and induced regulatory T cells in breast cancer patients.Nature communications · 2021Article
- Tumor resident regulatory T cells.Seminars in immunology · 2021Review
- Research Progress on the Role of Regulatory T Cell in Tumor Microenvironment in the Treatment of Breast Cancer.Frontiers in oncology · 2021Review
- IL-33 Signaling Alters Regulatory T Cell Diversity in Support of Tumor Development.Cell reports · 2019Article
- Regulatory T cells in cancer: where are we now?Immunology · 2019Article
- Regulation of regulatory T cells in cancer.Immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The involvement of effector T cells and regulatory T (T reg) cells in opposing and promoting solid organ carcinogenesis, respectively, is viewed as a shifting balance between a breach versus establishment of tolerance to tumor or self-antigens. We considered that tumor-associated T cells might promote malignancy via distinct mechanisms used by T cells in nonlymphoid organs to assist in their maintenance upon injury or stress. Recent studies suggest that T reg cells can participate in tissue repair in a manner separable from their immunosuppressive capacity. Using transplantable models of lung tumors in mice, we found that amphiregulin, a member of the epidermal growth factor family, was prominently up-regulated in intratumoral T reg cells. Furthermore, T cell-restricted amphiregulin deficiency resulted in markedly delayed lung tumor progression. This observed deterrence in tumor progression was not associated with detectable changes in T cell immune responsiveness or T reg and effector T cell numbers. These observations suggest a novel "nonimmune" modality for intratumoral T reg and effector T cells in promoting tumor growth through the production of factors normally involved in tissue repair and maintenance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.